NovoCure (NVCR) Cash from Investing Activities Growth (3y) (2017 - 2026)
NovoCure (NVCR) Cash from Investing Activities Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -253.01% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -11.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -6.88% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -472.46% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -16.93% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -111.03% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | NovoCure | 1.97 Bn | 1.53 Bn | 142.48 Mn | 22.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.86% |
| Mar 31, 2026 | -54.51% |
| Dec 31, 2025 | 66.63% |
| Sep 30, 2025 | 35.28% |
| Jun 30, 2025 | -38.64% |
| Mar 31, 2025 | 28.10% |
| Dec 31, 2024 | 64.56% |
| Sep 30, 2024 | -67.71% |
| Jun 30, 2024 | -422.96% |
| Mar 31, 2024 | 65.65% |
| Dec 31, 2023 | 29.28% |
| Sep 30, 2023 | -51.06% |
| Jun 30, 2023 | -61.24% |
| Mar 31, 2023 | 205.25% |
| Dec 31, 2022 | -39.91% |
| Sep 30, 2022 | -310.37% |
| Jun 30, 2022 | 349.97% |
| Mar 31, 2022 | -160.14% |
| Dec 31, 2021 | -553.42% |
| Sep 30, 2021 | 571.80% |